Stemcell Technologies Inc.

Stemcell Technologies Inc., a foreign-owned subsidiary of Canadian parent Stemcell Tecnologies, supplies specialized biological research materials, cell isolation and purification kits, cell culture media, automated cell separation instruments, and maintenance services to federal health agencies as a prime contractor operating exclusively in full-and-open competition with no set-aside designations.

The company operates from Kent, Washington and maintains a $10 million single-award Blanket Purchase Agreement with the National Institutes of Health Office of Logistics and Acquisition Operations running through December 31, 2026, which anchors its federal footprint and accounts for $10.1 million of the $18.7 million combined potential value across all recent awards. Stemcell Technologies Inc. competes on commercial product lines rather than custom development; the portfolio centers on proprietary brands including EasySep cell isolation kits, RoboSep-S automated immunomagnetic cell separators, STEMDIFF differentiation media, and complementary reagents and consumables. Representative prime work includes a $162,655 purchase order from the National Institute on Drug Abuse for RoboSep-S maintenance and repair services running through August 2029, a $99,528 purchase order from the National Institute of Allergy and Infectious Diseases for 160 EasySep Negative Human CD4 Kits supporting HIV research, a $86,359 purchase order from the Centers for Disease Control and Prevention in Pittsburgh for laboratory reagents, a $66,487 purchase order from the National Institute on Aging for a RoboSep-S automated cell separator, and a $59,293 purchase order from the CDC for intesticult cell cultures. Recent 2026 awards include a $45,839 purchase order from the Army Research, Development and Engineering Command for automated dissociator technology to process tissue samples, and a $12,569 definitive contract with Veterans Integrated Service Network 22 for a STEMCELL RoboSep PMI through March 2031.

Customer concentration is extreme and deliberate. The Department of Health and Human Services National Institutes of Health accounts for the dominant share of awards and dollars. The five highest-volume customers account for 51% of recent awards by count: the National Institute of Allergy and Infectious Diseases alone carries 63 awards worth $1.5 million; the NIAID Office of Acquisitions carries 45 awards worth $1.1 million; the National Heart, Lung, and Blood Institute holds 40 awards worth $518 thousand; the National Institute on Aging holds 29 awards worth $517 thousand; and the NIH Clinical Center holds 27 awards worth $775 thousand. The ranking by potential value reshuffles dramatically due to the BPA size: the NIH Office of Logistics and Acquisition Operations sits at the top with 4 awards valued at $10.1 million, followed by NIAID at $1.5 million, NIAID DEA Acquisitions at $1.1 million, the Clinical Center at $775 thousand, and the National Heart, Lung, and Blood Institute at $518 thousand. Activity has declined modestly — the vendor received 14 awards in 2022, 14 in 2023, 10 in 2024, 7 in 2025, and 2 through April 2026 — suggesting a maturing customer base consuming primarily consumables and service calls rather than expanding procurement. Only one award faces ultimate completion within the next twenty-four months (combined potential value $19 thousand), indicating minimal near-term recompete exposure on the prime side, though the BPA ceiling itself represents the principal at-risk vehicle.

Stemcell Technologies Inc. operates exclusively as a prime contractor; the source carries no sub-award activity. The federal footprint spans 398 awards across 37 customer agencies, but NIH institutes and health-focused civilian agencies dominate. Work is categorized across Testing Laboratories and Services (144 awards), Biological Product Manufacturing except Diagnostic (67 awards), Analytical Laboratory Instrument Manufacturing (58 awards), and In-Vitro Diagnostic Substance Manufacturing (18 awards) in primary NAICS, with PSC clustering in Drugs and Biologicals (151 awards), Laboratory Equipment and Supplies (80 awards), Chemicals (31 awards), and Maintenance/Repair of Laboratory Equipment (24 awards). The company's business model centers on streamlined procurement of off-the-shelf and lightly customized research materials through indefinite-delivery vehicles, particularly the NIH BPA, which enables federal institutes to rapidly procure critical supplies without individual competitive procurements. Combined dollars obligated total $7.9 million against $18.7 million combined potential value, indicating that many awards carry ceiling values higher than current obligations — a typical pattern for BPA calls and longer-term service contracts with option periods.